Ophthalmology Deals Up 1100% in 2026 — Here's the Data

Twelve ophthalmology deals closed between March 4 and September 4, 2026 — a 1100% increase over the single deal recorded in the prior six-month window (September 2025 to March 2026). This isn't a gentle uptick. It's a land grab driven by Big Pharma's desperation to fill mid-decade portfolio gaps as anti-VEGF franchises mature and gene therapy platforms finally reach clinical inflection points.

The Data — Ophthalmology Deal Activity, Period over Period

The raw numbers are small enough that percentage change alone can mislead — but the absolute shift from 1 to 12 deals in a single therapeutic area within six months is material by any standard. For context, ophthalmology typically accounts for 3–5% of total pharma licensing volume in a given year. This burst suggests the category punched well above its weight in mid-2026.

What's Driving the Trend

Pipeline gaps are the primary accelerant. The anti-VEGF market — anchored by Eylea and Lucentis biosimilars — is entering margin compression. Regeneron's Eylea HD bought time, but every major pharma company with an ophthalmology franchise knows the next decade belongs to longer-duration therapies, complement inhibitors, and gene therapies that can reduce or eliminate the injection burden. The companies that don't have these assets by 2027 will be playing catch-up for a decade. That urgency is compressing timelines and inflating valuations.

Gene therapy readiness is the second driver. AAV-based ocular gene therapies have moved from proof-of-concept (Luxturna's 2017 approval) to a broader pipeline targeting wet AMD, dry AMD with geographic atrophy, and inherited retinal diseases. Manufacturing scale-up — long the bottleneck — has improved enough that pharma acquirers now view these programs as commercially viable, not just scientifically interesting. The REGENXBIO–AbbVie and MeiraGTx–J&J deals are direct expressions of this thesis.

Complement biology validated by Apellis is the third catalyst. Syfovre's commercial launch, despite a rocky safety narrative around endophthalmitis, proved that geographic atrophy is a real market — not a regulatory graveyard. Biogen's $5.6B move on Apellis signals that large-cap buyers believe the complement class will expand beyond GA into broader retinal indications. That single deal reshaped the risk calculus for every complement-pathway asset in development.

Notable Deals

Biogen–Apellis ($5.6B) is the headline transaction and the largest ophthalmology deal in years. At $5.6B total deal value with the entire amount structured as upfront consideration, Biogen paid a premium that reflects both Syfovre's commercial trajectory and the strategic value of owning the leading complement franchise outright. For Biogen, this is a diversification play away from neuro — and a bet that retinal complement biology has legs beyond GA. Benchmark this against recent ophthalmology deal structures using the Ambrosia calculator and the gap between this deal and historical norms is stark.

REGENXBIO–AbbVie is the gene therapy signal. AbbVie already has a deep ophthalmology commercial footprint through its Allergan Eye Care unit. Adding REGENXBIO's AAV platform — particularly its RGX-314 program for wet AMD — gives AbbVie a potential one-and-done alternative to chronic anti-VEGF injections. Financial terms were not disclosed, but the strategic logic is clear: AbbVie is building a post-Eylea-biosimilar portfolio.

MeiraGTx–J&J ($130M upfront) follows a similar gene therapy thesis but at earlier-stage economics. The $130M upfront for MeiraGTx's retinal gene therapy platform is a reasonable entry point for J&J, which has historically under-indexed in ophthalmology relative to its medtech peers. Compare this to Deal Benchmarks for gene therapy licensing structures — the upfront is in line with Phase 1/2 ocular gene therapy precedents.

EyeBio–Merck and AbbVie–Aldeyra round out the trend with undisclosed terms. EyeBio's bispecific antibody platform targeting VEGF and ANG2 caught Merck's attention — likely as a hedge against Regeneron's dominance. Aldeyra's reproxalap, a novel RASP inhibitor for dry eye disease, gives AbbVie an entry into anterior segment inflammation beyond Restasis/Xiidra dynamics.

What This Means for BD Teams Right Now

This is a seller's market — but only for specific modalities. If you have a differentiated retinal gene therapy, a complement-pathway inhibitor with clean safety data, or a bispecific targeting VEGF-plus-something, your leverage has never been higher. Upfronts are rising. Buyer urgency is real. The window is now.

For buyers, waiting is expensive. The Apellis deal at $5.6B sets a new anchor for complement-class valuations. Every remaining independent complement asset — and there aren't many — just got more expensive. Gene therapy platforms are following the same trajectory. BD teams that are still running exploratory diligence on ophthalmology targets they identified six months ago are already behind. The bid-ask spread is widening in the seller's favor, and competitive auction dynamics are emerging for the best assets.

Deal structures are shifting toward higher upfronts. The Biogen–Apellis deal was 100% upfront. MeiraGTx–J&J was $130M upfront against $130M TDV — also effectively all upfront. This pattern suggests sellers are demanding, and getting, cash certainty rather than milestone-heavy structures. BD teams should adjust their term sheet templates accordingly. Back-loaded deals with 80% in milestones are going to lose competitive processes in this environment. Use Solidus to model how your proposed structure compares to these recent precedents.

Anterior segment is the overlooked opportunity. The bulk of deal activity and premium valuations are in retina and gene therapy. Dry eye, glaucoma, and presbyopia assets remain relatively undervalued on a risk-adjusted basis. If you're a buyer looking for value, the anterior segment is where the arbitrage lives — for now.

Benchmark your deal against current market rates using the Ambrosia calculator. With ophthalmology licensing 2026 activity at a decade high, having real-time comps isn't optional — it's table stakes for any negotiation in this space.